Market data not licensed for redistribution.
Hyundai Bioscience
048410 ยท KOSDAQ ยท Manufacture of Other Chemical Products
Close
Source: Financial Services Commission stock price data (data.go.kr), updated once a day.
Daily price, 1 year
Key statistics
Market cap (KRW bn)โ
PERโ
PBRโ
ROE %-27.7
Debt ratio % (liabilities / equity)27
Revenue TTM (KRW bn)3.3
Op. profit TTM (KRW bn)-19.3
Dividend yield %โ
Basis: market cap at โฆ; equity = total equity (consolidated if available) at 2026.06.30; net income = trailing 12 months to 2026.06.30 (consolidated). PER is not shown when TTM net income is negative.
Upcoming risk events
Next 90 days for this company, plus macro events tagged with this ticker or its sector. Not a recommendation.
| 2026-11-07 | China trade data (estimated date) (2026-10) estimated โ China is Korea's biggest export market; weak imports hit chemicals, steel and cosmetics. | Medium |
| 2026-11-09 | China CPI and PPI (estimated date) (2026-10) estimated โ China's demand and factory prices matter for Korean cosmetics, chemicals and steel. | Medium |
| 2026-12-07 | China trade data (estimated date) (2026-11) estimated โ China is Korea's biggest export market; weak imports hit chemicals, steel and cosmetics. | Medium |
| 2026-12-09 | China CPI and PPI (estimated date) (2026-11) estimated โ China's demand and factory prices matter for Korean cosmetics, chemicals and steel. | Medium |
| 2027-01-09 | China CPI and PPI (estimated date) (2026-12) estimated โ China's demand and factory prices matter for Korean cosmetics, chemicals and steel. | Medium |
| 2027-01-13 | China trade data (estimated date) (2026-12) estimated โ China is Korea's biggest export market; weak imports hit chemicals, steel and cosmetics. | Medium |
Other scheduled dates (routine, not risks) (2)
- 2026-11-09 ยท Routine schedule: record date
- 2026-12-09 ยท Routine schedule: extraordinary shareholder meeting
Annual results (KRW bn)
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue | 9.2 | 7.9 | 9.5 | 15.1 | 3.5 |
| Operating profit | -9.8 | -26.4 | -9.8 | 0.8 | -18.2 |
| Net income | -20.1 | -15.8 | -14.5 | -6.9 | -22.1 |
Quarterly results (KRW bn, 3 months)
| 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | 2026Q1 | 2026Q2 | |
|---|---|---|---|---|---|---|
| Revenue | 0.7 | 0.3 | 0.6 | 1.9 | 0.3 | 0.5 |
| Operating profit | -4.3 | -4.8 | -4.6 | -4.4 | -4.7 | -5.5 |
| Net income | -6.1 | -4.3 | -7.0 | -4.7 | -5.3 | -11.6 |
Largest shareholder
As of the 2025 annual report: (์ฃผ)์จ์คํ and related parties hold 10.24% of common shares.
Recent disclosures
| Date | Filing | Summary | |
|---|---|---|---|
| 2026-10-23 | Shareholder meeting ์ฃผ์ฃผ๋ช ๋ถํ์๊ธฐ๊ฐ๋๋๊ธฐ์ค์ผ์ค์ | DART original | |
| 2026-10-23 | Shareholder meeting ์ฃผ์ฃผ์ดํ์์ง๊ฒฐ์ (์์์ฃผ์ฃผ์ดํ) | DART original | |
| 2026-10-13 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-10-13 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original | |
| 2026-10-02 | Periodic report (annual/half/quarterly) [๊ธฐ์ฌ์ ์ ]๋ฐ๊ธฐ๋ณด๊ณ ์ (2026.06) | DART original | |
| 2026-09-30 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original | |
| 2026-09-16 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original | |
| 2026-09-16 | Insider / major-holder ownership report ์์ใ์ฃผ์์ฃผ์ฃผํน์ ์ฆ๊ถ๋ฑ์์ ์ํฉ๋ณด๊ณ ์ | DART original | |
| 2026-09-08 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original | |
| 2026-09-04 | Clinical trial / regulatory approval ํฌ์ํ๋จ๊ด๋ จ์ฃผ์๊ฒฝ์์ฌํญ(์์์ํ๊ณํ๋ณ๊ฒฝ์น์ธ์ ์ฒญ) (์ ๋ฆฝ์ ์ ์น๋ฃ์ CPPCA07์ 1์ ์์์ํ๊ณํ ๋ณ๊ฒฝ์น์ธ ์ ์ฒญ) | DART original | |
| 2026-08-13 | Periodic report (annual/half/quarterly) [์ฒจ๋ถ์ถ๊ฐ]๋ฐ๊ธฐ๋ณด๊ณ ์ (2026.06) | DART original | |
| 2026-08-06 | Insider / major-holder ownership report ์ฃผ์๋ฑ์๋๋๋ณด์ ์ํฉ๋ณด๊ณ ์(์ผ๋ฐ) | DART original |
Past material filings and price reaction (market-adjusted)
| Date | Filing type | On the news (vs. market) | Next day (vs. market) | 20 days (vs. market) |
|---|---|---|---|---|
| 2026-09-04 | Clinical trial / regulatory approval | -0.2% | +0.2% | +7.1% |
| 2026-06-15 | Convertible bond issuance | -0.1% | +2.0% | -4.3% |
| 2026-04-17 | Clinical trial / regulatory approval | +3.9% | +3.0% | -16.5% |
| 2026-03-06 | Clinical trial / regulatory approval | -4.5% | +11.1% | -2.8% |
| 2026-02-25 | Revenue/profit change >=30% (15% large caps) | +2.2% | -15.5% | -26.9% |
| 2025-11-12 | Clinical trial / regulatory approval | -1.1% | -1.7% | -3.4% |
| 2025-11-07 | Clinical trial / regulatory approval | -0.7% | +0.7% | +8.3% |
| 2025-10-13 | Clinical trial / regulatory approval | -0.2% | +2.8% | -6.6% |
| 2025-09-24 | Convertible bond issuance | -0.4% | +0.9% | -7.5% |
| 2025-09-16 | Clinical trial / regulatory approval | +0.9% | -0.7% | -8.9% |
For information only, not investment advice. Data may be delayed or inaccurate. Full disclaimer โ Data: OpenDART (FSS), stock prices: official previous-day close from the Financial Services Commission (data.go.kr) and FinanceData/marcap history, index data via FinanceDataReader, FX: ECB reference rates, crypto data from Upbit, Bithumb and Binance public APIs.
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view
Market data not licensed for redistribution.
ยฉ Crypvu ยท Crypto market view